BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8231243)

  • 1. Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate.
    Blatt J; Howrie DL; Wollman MR; Phebus C; Mirro J
    Leukemia; 1993 Nov; 7(11):1734-7. PubMed ID: 8231243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
    Yang CH; Yang LJ; Jaing TH; Chan HL
    Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
    Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
    J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
    Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
    J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function and methotrexate clearance in children with newly diagnosed leukemia.
    Murry DJ; Synold TW; Pui CH; Rodman JH
    Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
    Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
    Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
    Thompson PA; Murry DJ; Rosner GL; Lunagomez S; Blaney SM; Berg SL; Camitta BM; Dreyer ZE; Bomgaars LR
    Cancer Chemother Pharmacol; 2007 May; 59(6):847-53. PubMed ID: 17136402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of methotrexate given intrathecally to children with acute lymphoblastic leukemia.
    Skibińska L; Daszkiewicz P; Michalewska D; Radwańska U
    Pol J Pharmacol Pharm; 1988; 40(2):135-43. PubMed ID: 3237563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raised plasma methotrexate concentrations following intrathecal administration in children with renal dysfunction.
    Gregory RE; Pui CH; Crom WR
    Leukemia; 1991 Nov; 5(11):999-1003. PubMed ID: 1961043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between methotrexate and chloral hydrate.
    Dao K; Ivanyuk A; Buclin T; Beck-Popovic M; Diezi M
    Pediatr Blood Cancer; 2013 Mar; 60(3):518-20. PubMed ID: 23151940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.